Affiliation:
1. C‐ENDO Diabetes and Endocrinology Clinic Calgary Alberta Canada
2. Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases University of Bari Aldo Moro Bari Italy
3. Division of Endocrinology, Department of Medicine, Grady Memorial Hospital Emory University School of Medicine Atlanta Georgia USA
4. Eli Lilly and Company Indianapolis Indiana USA
Abstract
AbstractAimTo assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg).Materials and MethodsHbA1c and body weight data at 40 weeks (SURPASS‐1, ‐2 and ‐5) and 52 weeks (SURPASS‐3 and ‐4) were analysed by trial.ResultsAcross the SURPASS clinical trials, HbA1c reductions from baseline were observed in 96%‐99%, 98%‐99% and 94%‐99% of participants treated with tirzepatide 5, 10 and 15 mg, respectively. Moreover, 87%‐94%, 88%‐95% and 88%‐97% of participants, respectively, experienced weight loss associated with HbA1c reductions. Statistically significant associations (correlation coefficients ranging from 0.1438 to 0.3130 across studies; P ≤ .038) between HbA1c and body weight changes were observed with tirzepatide in SURPASS‐2, ‐3, ‐4 (all doses) and ‐5 (tirzepatide 5 mg only).ConclusionsIn this post hoc analysis, consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg. A statistically significant but modest association between HbA1c and body weight change was observed in SURPASS‐2, SURPASS‐3 and SURPASS‐4, suggesting that both weight‐independent and weight‐dependent mechanisms are responsible for the tirzepatide‐induced improvement in glycaemic control.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献